Ascletis Pharma Inc. (ASCLF)
USD 0.24
(0.0%)
USD 0.24
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -321.7 Million CNY | 86.96% |
| 2022 | -2.46 Billion CNY | 1.05% |
| 2021 | -2.49 Billion CNY | 8.1% |
| 2020 | -2.71 Billion CNY | 9.14% |
| 2019 | -2.98 Billion CNY | 5.92% |
| 2018 | -3.17 Billion CNY | -422.46% |
| 2017 | -607.36 Million CNY | -44.97% |
| 2016 | -418.97 Million CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -342.99 Million CNY | -6.62% |
| 2024 Q2 | -342.99 Million CNY | 2.58% |
| 2023 Q2 | -466.65 Million CNY | 0.4% |
| 2023 Q1 | -468.52 Million CNY | 81.01% |
| 2023 FY | -321.7 Million CNY | 86.96% |
| 2023 Q4 | -321.7 Million CNY | 1.74% |
| 2023 Q3 | -327.41 Million CNY | 29.84% |
| 2022 Q2 | -2.48 Billion CNY | 0.05% |
| 2022 FY | -2.46 Billion CNY | 1.05% |
| 2022 Q1 | -2.48 Billion CNY | 0.39% |
| 2022 Q4 | -2.46 Billion CNY | -513.66% |
| 2022 Q3 | -401.94 Million CNY | 83.81% |
| 2021 FY | -2.49 Billion CNY | 8.1% |
| 2021 Q3 | -2.49 Billion CNY | 3.09% |
| 2021 Q4 | -2.49 Billion CNY | 0.06% |
| 2021 Q1 | -2.57 Billion CNY | 5.03% |
| 2021 Q2 | -2.57 Billion CNY | 0.08% |
| 2020 Q2 | -2.99 Billion CNY | 0.06% |
| 2020 Q3 | -2.71 Billion CNY | 9.37% |
| 2020 Q4 | -2.71 Billion CNY | 0.04% |
| 2020 FY | -2.71 Billion CNY | 9.14% |
| 2020 Q1 | -2.99 Billion CNY | -0.35% |
| 2019 Q2 | -3.03 Billion CNY | 0.07% |
| 2019 FY | -2.98 Billion CNY | 5.92% |
| 2019 Q4 | -2.98 Billion CNY | 0.07% |
| 2019 Q3 | -2.98 Billion CNY | 1.67% |
| 2019 Q1 | -3.04 Billion CNY | 4.19% |
| 2018 Q1 | -526.02 Million CNY | 13.39% |
| 2018 FY | -3.17 Billion CNY | -422.46% |
| 2018 Q4 | -3.17 Billion CNY | 0.0% |
| 2018 Q3 | -3.17 Billion CNY | -417.59% |
| 2018 Q2 | -613.07 Million CNY | -16.55% |
| 2017 FY | -607.36 Million CNY | -44.97% |
| 2017 Q1 | 424.58 Million CNY | 0.0% |
| 2017 Q3 | -607.36 Million CNY | 0.0% |
| 2017 Q4 | -607.36 Million CNY | 0.0% |
| 2016 FY | -418.97 Million CNY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 2140.862% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 7912.023% |
| SQZ Biotechnologies Company | -36.23 Million USD | -787.745% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 851.761% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | -5002.701% |
| Mesoblast Limited | 55.85 Million USD | 675.924% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 34796.49% |
| Genus plc | 190.6 Million USD | 268.783% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 14488.425% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 26601.704% |
| Marizyme, Inc. | 18.56 Million USD | 1832.46% |
| ContraFect Corporation | -6.02 Million USD | -5238.55% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 47408.971% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | 239035.97% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 27942.559% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 14447.349% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 5947.093% |
| MultiCell Technologies, Inc. | 90.04 USD | 357286861.439% |
| Accustem Sciences Inc. | -733.97 Thousand USD | -43729.788% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 2584.945% |
| EV Biologics, Inc. | 1.36 Million USD | 23616.653% |
| Q BioMed Inc. | 4.06 Million USD | 8023.654% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 1152.893% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 51790.168% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 32023.776% |
| Biomind Labs Inc. | 711.4 Thousand USD | 45320.705% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 109.8 Million USD | 392.977% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 2611.996% |
| Skye Bioscience, Inc. | -5.72 Million USD | -5522.778% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 37496.613% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | 230208.581% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 5795.466% |
| IMV Inc. | 7.67 Million USD | 4293.992% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | 1619373.167% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 14709.617% |
| GB Sciences, Inc. | 1.74 Million USD | 18511.152% |
| Alpha Cognition Inc. | -183.78 Thousand USD | -174939.176% |
| HST Global, Inc. | 96.79 Thousand USD | 332459.778% |
| CSL Limited | 10.52 Billion USD | 103.056% |
| Halberd Corporation | 144.72 Thousand USD | 222390.476% |
| Enzolytics Inc. | 981.65 Thousand USD | 32871.256% |
| Resverlogix Corp. | 6.45 Million USD | 5086.839% |
| Affymax, Inc. | -5.59 Million USD | -5647.74% |
| SYBLEU INC | 473.71 Thousand USD | 68010.385% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | -47694.72% |
| argenx SE | -2.02 Billion USD | 84.144% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 840.666% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | -584.295% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 11976.956% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | -3539.188% |
| AVAX Technologies, Inc. | -5.9 Million USD | -5349.597% |
| Zenith Capital Corp. | 10.06 Thousand USD | 3196652.067% |
| Genscript Biotech Corporation | -1.06 Billion USD | 69.689% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | 160603.812% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 13582.666% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | 195652.219% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 631.335% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 16189.941% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -2.57 Million USD | -12417.393% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 89533.432% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 1686.61% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | -1756101.55% |
| BioStem Technologies, Inc. | 4.47 Million USD | 7293.654% |
| ONE Bio Corp. | 9.04 Million USD | 3658.626% |
| Reve Technologies, Inc. | 201.25 Thousand USD | 159948.251% |
| Burzynski Research Institute, Inc. | -1310.00 USD | -24557228.244% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | 156101.203% |
| Agentix Corp. | 37.63 Thousand USD | 854982.942% |
| LadRx Corporation | -2.03 Million USD | -15697.0% |
| Cell Source, Inc. | 9.23 Million USD | 3584.64% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | -1576247.511% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 50748.255% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 50748.255% |
| NovAccess Global Inc. | 2.17 Million USD | 14867.325% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 4649.601% |
| Itoco Inc. | 228.3 Thousand USD | 141008.434% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | 236663.987% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 6589.833% |
| Kadimastem Ltd | -253.1 Thousand USD | -127003.302% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 80155.195% |
| CytoDyn Inc. | 20.26 Million USD | 1687.706% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | -49721847.45% |
| Mobile Lads Corp. | 484.23 Thousand USD | 66535.304% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | -3470866.753% |
| Qrons Inc. | 351.42 Thousand USD | 91641.344% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 4274.681% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | -128776.292% |
| Rebus Holdings, Inc. | 305 Thousand USD | 105575.738% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 7317.846% |
| International Stem Cell Corporation | 2.59 Million USD | 12520.888% |
| Bioxytran, Inc. | 1.89 Million USD | 17041.315% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | 515539.091% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 14850.837% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 9468.113% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 3861.265% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 41738.375% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | -25636.08% |
| Neutra Corp. | 52.18 Thousand USD | 616538.96% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | -12824.91% |
| PureTech Health plc | -167.19 Million USD | -92.408% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | -131255.856% |
| IXICO plc | -4.44 Million USD | -7138.04% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 2533.626% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 686.5% |
| CSL Limited | 10.52 Billion USD | 103.056% |
| Cellectis S.A. | -43.81 Million USD | -634.161% |